In this issue:
Efficacy of TA
Cadonilimab plus chemotherapy
Induction therapy, PFS and OS
Addition of pembrolizumab to chemoradiotherapy
Safety and response rates of bintrafusp alfa
Comparison of CEE plus MPA and CEE-alone
SLN biopsy and survival
Pembrolizumab plus adjuvant chemotherapy
Assessing new 2023 FIGO staging system
LVSI and risk of disease progression
Please login below to download this issue (PDF)